Lipossomal preparation of idarubicin: new technologies applied to development of alternatives to breast cancer treatment.

• Grant number: 15/21447-9
• Support Opportunities: Regular Research Grants
• Duration: August 01, 2016 - July 31, 2018
• Field of knowledge: Health Sciences - Pharmacy - Medicines Analysis and Control
• Principal Investigator: Terezinha de Jesus Andreoli Pinto
• Grantee: Terezinha de Jesus Andreoli Pinto
• Host Institution: Faculdade de Ciências Farmacêuticas (FCF). Universidade de São Paulo (USP). São Paulo , SP, Brazil
• Associated researchers: Ana Paula Valagão Amadeu Do Serro ; Daniela Dal Molim Ghisleni ; Irene Satiko Kikuchi ; Marina de Souza Braga ; Raquel Sofia Cardoso Galante

Abstract

Anthracyclines have been used in drug therapy since the 60s, the first were doxorubicin and daunorricibina, and their similar the 1st looking for a greater allocation to the target organ and reduced cardiotoxicity were epirubicin, useful alternative to doxorubicin, and idarubicin, alternative aunorricibina. Idarubicin is 10 times more cytotoxic than daunorricibina and greater activity incultured human adenocarcinoma cell lines. Furthermore, it has been demonstrated dose proportional for an anti-proliferative effect on cell line of human ovarian cancer, cervix, breast and melanoma. Currently, two fronts are targets for study of the anthracyclines, the first is the development of targeted drug formulations, and nanocarriers such as liposomes, and the second in the development of new analogues. Liposomes are used in several areas, among them there are the liposomal formulations encapsulating anthracycline leading to preferential accumulation in tumor areas, prolonged drug release in the tumor microenvironment, partial avoidance of resistance to tumor and a limited accumulation in healthy tissues, decreasing thus cardiotoxicity. It has been demonstrated the efficiency of liposomal anthracyclines doxorubicin and daunorubicin involving. In this project the focus will be the development of a preaparação innovative liposomal idarubicin, able to act as an alternative to the usual treatment of breast cancer, for this, it will be used sterilization ozone base that once demonstrated the effectiveness of sterilization allow the production process is performed in non- aseptic conditions reducing costs for production on an industrial scale. Thus, this study aims to develop a differentiated sterile liposomal preparation of available, idarubicin base for human use, which is characterized by having less cardiotoxicity, increased targeting to tumor site resulting in higher quality, efficiency and safety. (AU)